Sinovac

SINOVAC Biotech is urging shareholders to vote against proposals to replace the board, citing its efforts to restore shareholder value, including dividend payments and a strategic realignment. The company launched www.VoteSinovac.com and filed an investor presentation with the SEC, highlighting the board’s commitment to maximize shareholder investment, defend against litigation from a dissenting investor group, and potentially relist on the Hong Kong Stock Exchange.

SINOVAC Biotech Ltd. successfully defended against a legal challenge in New York, paving the way for its declared $55.00 per share dividend. The court denied Advantech/Prime’s petition, a move that supports the current board’s actions and their plans for further shareholder payouts. Shareholders are encouraged to vote against proposals to oust the current board.

Prime Success L.P., holding an 8% stake in Sinovac Biotech, issued a statement criticizing the company’s upcoming shareholder meeting on July 8, 2025, and the actions of the current board (“1Globe Activist Board”). Prime Success, a large shareholder, accuses the board of misleading statements regarding dividend distribution timing and manipulating facts. They advocate for a dividend payout before the meeting and urge shareholders to vote for a new board nominated by SAIF, emphasizing the critical need for competent leadership focused on the company’s long-term success.